The September 2017 issue of Pharmafocus is now live!
pharmafile | August 30, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Cancer, Cancer Research UK, MSD, Pharmafocus, President trump, Takeda, Trump, charlottesville, life sciences, oncology, pharmaceuticals, phatmaÂ
The September edition of Pharmafocus is now available – click here to read online.
President Trump continues to clash with industry and sow uncertainty for those in the manufacturing sector. August saw the dissolution of the President’s Manufacturing Council after his responses to the Charlottesville violence were slammed by a number of board members, led by MSD CEO Kenneth Frazier, sparking an exodus from the council as the resignations from the council poured in. You can read the full details in our front page story.
This month, Pharmafocus delves into the latest happenings in cancer treatment in a special oncology feature. With contributions from Takeda Oncology, the European CanCer Organisation (ECCO), Cancer Research UK and Leukaemia CARE, the feature offers a wealth of expertise and cutting-edge insight into the field of cancer treatment today.
Elsewhere in the issue, Fiona Stevens of Gil, Jennings & Every gives her expert opinion on the shocking final decision of the legal battle over the rights to anti-cancer drug permextred, and we investigate the news that scientists have found a cure for peanut allergy. And don’t miss our in-depth features on the EMA’s ambitious clinical trial harmonisation project, and the important impact of accelerated access medicine schemes.
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
